Citations

Mayo Clinic

Showing 10 of 108599 citations.

Advancements in Radiation Techniques for Gastric Cancer
Callister, Matthew D., Gunderson, Leonard L.

Journal of the National Comprehensive Cancer Network | April 14, 2017 | Volume: 8 | Issue: 4 | Pages: 428-436

10.6004/jnccn.2010.0032 | PMID 20410335 Get It

All but the earliest cases of nonmetastatic gastric cancer represent a therapeutic challenge given the high propensity of these patients to develop locoregional and distant relapse. Neoadjuvant or adjuvant strategies that include chemoradiotherapy or chemotherapy have been associated with significant toxicity, but also improvement in patient survival. Technologic advances in the planning and delivery of radiotherapy (RT) have enabled significant progress in the accuracy and conformality of radiation treatment. Four-dimensional CT and image-guided RT improve the accuracy of radiation treatment. Three-dimensional RT and intensity-modulated RT allow increased conformality of radiation dose distribution, sparing of normal organs, and providing opportunity for dose escalation. Initial clinical experience with these technologies shows favorable tolerance and outcomes.
Nonhormonal Management of Hot Flashes for Women on Risk Reduction Therapy
Loprinzi, Charles L. , Sideras, Kostandinos

Journal of the National Comprehensive Cancer Network | April 14, 2017 | Volume: 8 | Issue: 10 | Pages: 1171-1179

10.6004/jnccn.2010.0086 | PMID 20971841 Get It

Hot flashes are very common in women in menopause and can have a detrimental effect on quality of life. Women on risk reduction therapy are particularly prone because treatments, such as tamoxifen, raloxifene, or oophorectomy, have the potential to exacerbate these symptoms. Hormonal treatments, despite the fact that they represent the most effective therapies, are not used for the treatment of hot flashes in these women because of concerns that they may increase the risk for breast cancer. As a result, several nonhormonal therapies have been tested in randomized placebo-controlled trials and shown to be effective, such as paroxetine, venlafaxine, desvenlafaxine, fluoxetine, citalopram, gabapentin, and pregabalin. In addition, several nonpharmacologic therapies have been tested with various successes. An additional consideration is how some of those drugs, especially fluoxetine and paroxetine, interact with the metabolism of tamoxifen. This article discusses these issues, and provides some recommendations regarding use of nonhormonal therapies for treating hot flashes in women on risk reduction therapy, with an emphasis on pharmacogenomic considerations.
Human-derived gut microbiota modulates colonic secretion in mice by regulating 5-HT3receptor expression via acetate production
Bhattarai, Yogesh , Schmidt, Bradley A., Larson, Eric D. , Grover, Madhusudan , Farrugia, Gianrico , Kashyap, Purna , Linden, David R. , Beyder, Arthur , Bhattarai, Y

American Journal of Physiology-Gastrointestinal and Liver Physiology | April 14, 2017 | Volume: 313 | Issue: 1 | Pages: G80-G87

10.1152/ajpgi.00448.2016 | PMID 28408644 Get It

Serotonin [5-hydroxytryptamine (5-HT)], an important neurotransmitter and a paracrine messenger in the gastrointestinal tract, regulates intestinal secretion by its action primarily on 5-HT3and 5-HT4receptors. Recent studies highlight the role of gut microbiota in 5-HT biosynthesis. In this study, we determine whether human-derived gut microbiota affects host secretory response to 5-HT and 5-HT receptor expression. We used proximal colonic mucosa-submucosa preparation from age-matched Swiss Webster germ-free (GF) and humanized (HM; ex-GF colonized with human gut microbiota) mice. 5-HT evoked a significantly greater increase in short-circuit current (Δ Isc) in GF compared with HM mice. Additionally, 5-HT3receptor mRNA and protein expression was significantly higher in GF compared with HM mice. Ondansetron, a 5-HT3receptor antagonist, inhibited 5-HT-evoked Δ Iscin GF mice but not in HM mice. Furthermore, a 5-HT3receptor-selective agonist, 2-methyl-5-hydroxytryptamine hydrochloride, evoked a significantly higher Δ Iscin GF compared with HM mice. Immunohistochemistry in 5-HT3A-green fluorescent protein mice localized 5-HT3receptor expression to enterochromaffin cells in addition to nerve fibers. The significant difference in 5-HT-evoked Δ Iscbetween GF and HM mice persisted in the presence of tetrodotoxin (TTX) but was lost after ondansetron application in the presence of TTX. Application of acetate (10 mM) significantly lowered 5-HT3receptor mRNA in GF mouse colonoids. We conclude that host secretory response to 5-HT may be modulated by gut microbiota regulation of 5-HT3receptor expression via acetate production. Epithelial 5-HT3receptor may function as a mediator of gut microbiota-driven change in intestinal secretion.NEW & NOTEWORTHY We found that gut microbiota alters serotonin (5-HT)-evoked intestinal secretion in a 5-HT3receptor-dependent mechanism and gut microbiota metabolite acetate alters 5-HT3receptor expression in colonoids.View this article's corresponding video summary at https://www.youtube.com/watch?v=aOMYJMuLTcw&feature=youtu.be .
External Arrhythmia Ablation Using Photon Beams
Deisher, A., Takami, Mitsuru , Kruse, Jon J. , Song, Limin, Anderson, Sarah , Cusma, Jack T., Parker, Kay D., Johnson, Susan B., Asirvatham, Samuel J. , Miller, Robert C. , Herman, Michael , Packer, Douglas L. , Lehmann, H. Immo , Deisher, Amanda J, Anderson, Sarah E, Herman, Michael G., Asirvatham, Samuel J

Circulation: Arrhythmia and Electrophysiology | April 13, 2017 | Volume: 10 | Issue: 4 | Pages: No page available

10.1161/circep.116.004304 | PMID 28408649 Get It

Background— This study sought to investigate external photon beam radiation for catheter-free ablation of the atrioventricular junction in intact pigs. Methods and Results— Ten pigs were randomized to either sham irradiation or irradiation of the atrioventricular junction (55, 50, 40, and 25 Gy). Animals underwent baseline electrophysiological evaluation, cardiac gated multi-row computed tomographic imaging for beam delivery planning, and intensity-modulated radiation therapy. Doses to the coronary arteries were optimized. Invasive follow-up was conducted ≤4 months after the irradiation. A mean volume of 2.5±0.5 mL was irradiated with target dose. The mean follow-up length after irradiation was 124.8±30.8 days. Out of 7 irradiated animals, complete atrioventricular block was achieved in 6 animals of all 4 dose groups (86%). Using the same targeting margins, ablation lesion size notably increased with the delivered dose because of volumetric effects of isodose lines around the target volume. The mean macroscopically calculated atrial lesion volume for all 4 dose groups was 3.8±1.1 mL, lesions extended anteriorly into the interventricular septum. No short-term side effects were observed. No damage was observed in the tissues of the esophagus, phrenic nerves, or trachea. However, histology revealed in-field beam effects outside of the target volume. Conclusions— Single-fraction doses as low as 25 Gy caused a lesion with interruption of cardiac impulse propagation using this respective target volume. With doses of ≤55 Gy, maximal point-doses to coronary arteries could be kept <7Gy, but target conformity of lesions was not fully achieved using this approach.
Cardiac autonomic control and complexity during sleep are preserved after chronic sleep restriction in healthy subjects
Covassin, Naima , Calvin, Andrew D. , Singh, Prachi , Bukartyk, Jan , Wang, Shiang, Montano, Nicola , Tobaldini, Eleonora, Calvin, Andrew, Tobaldini, Eleonora , Wang, Shiang, Somers, Virend K. , Singh, Prachi , Calvin, Andrew D , Montano, Nicola

Physiological Reports | April 13, 2017 | Volume: 5 | Issue: 7 | Pages: e13197

10.14814/phy2.13197 | PMID 28408635 Get It

Electroencephalography Predicts Poor and Good Outcomes After Cardiac Arrest: A Two-Center Study*
Rossetti, Andrea O. , Quiroga, Diego F. Tovar, Juan, Elsa , White, Roger D., Ben‐Hamouda, Nawfel , Oddo, Mauro , Nový, Jan , Britton, Jeffrey W. , Rabinstein, Alejandro A.

Critical Care Medicine | April 13, 2017 | Volume: 45 | Issue: 7 | Pages: e674-e682

10.1097/ccm.0000000000002337 | PMID 28406812 Get It

Objective:The prognostic role of electroencephalography during and after targeted temperature management in postcardiac arrest patients, relatively to other predictors, is incompletely known. We assessed performances of electroencephalography during and after targeted temperature management toward good and poor outcomes, along with other recognized predictors.Design:Cohort study (April 2009 to March 2016).Setting:Two academic hospitals (Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Mayo Clinic, Rochester, MN).Patients:Consecutive comatose adults admitted after cardiac arrest, identified through prospective registries.Interventions:All patients were managed with targeted temperature management, receiving prespecified standardized clinical, neurophysiologic (particularly, electroencephalography during and after targeted temperature management), and biochemical evaluations.Measurements and Main Results:We assessed electroencephalography variables (reactivity, continuity, epileptiform features, and prespecified “benign” or “highly malignant” patterns based on the American Clinical Neurophysiology Society nomenclature) and other clinical, neurophysiologic (somatosensory-evoked potential), and biochemical prognosticators. Good outcome (Cerebral Performance Categories 1 and 2) and mortality predictions at 3 months were calculated. Among 357 patients, early electroencephalography reactivity and continuity and flexor or better motor reaction had greater than 70% positive predictive value for good outcome; reactivity (80.4%; 95% CI, 75.9–84.4%) and motor response (80.1%; 95% CI, 75.6–84.1%) had highest accuracy. Early benign electroencephalography heralded good outcome in 86.2% (95% CI, 79.8–91.1%). False positive rates for mortality were less than 5% for epileptiform or nonreactive early electroencephalography, nonreactive late electroencephalography, absent somatosensory-evoked potential, absent pupillary or corneal reflexes, presence of myoclonus, and neuron-specific enolase greater than 75 µg/L; accuracy was highest for early electroencephalography reactivity (86.6%; 95% CI, 82.6–90.0). Early highly malignant electroencephalography had an false positive rate of 1.5% with accuracy of 85.7% (95% CI, 81.7–89.2%).Conclusions:This study provides class III evidence that electroencephalography reactivity predicts both poor and good outcomes, and motor reaction good outcome after cardiac arrest. Electroencephalography reactivity seems to be the best discriminator between good and poor outcomes. Standardized electroencephalography interpretation seems to predict both conditions during and after targeted temperature management.
Nano‐curcumin safely prevents streptozotocin‐induced inflammation and apoptosis in pancreatic beta cells for effective management of Type 1 diabetes mellitus
Ganugula, Raghu , Jaisamut, Patcharawalai , Wiwattanapatapee, Ruedeekorn , Venkatpurwar, Vinod, Hoffmann, Aline Rodrigues , Basu, Rita , Kumar, M. N. V. Ravi , Majeti, Naga Venkata Ravi Kumar , Arora, Meenakshi , Jørgensen, Heather G. , Zhou, Beiyan , Guo, Shaodong

British Journal of Pharmacology | April 13, 2017 | Volume: 174 | Issue: 13 | Pages: 2074-2084

10.1111/bph.13816 | PMID 28409821 Get It

Background and PurposeApproaches to prevent selective and progressive loss of insulin‐producing beta cells in Type 1 diabetes mellitus (T1DM) will help to manage this prevalent and devastating disease. Curcumin (CUR), a natural anti‐inflammatory substance, suppresses diabetes‐associated inflammation and cell death. However, very high doses need to be used because of poor oral bioavailability, making it difficult to translate the anti‐inflammatory actions to clinical situations.Experimental ApproachWe have prepared biodegradable nanosystems encapsulating curcumin (nCUR), resulting in at least nine‐fold improvement in oral bioavailability. Here, we tested the ability of nCUR to prevent streptozotocin (STZ)‐induced inflammation and apoptosis in pancreatic islets and beta cells, in rats.Key ResultsNon‐fasted rats pretreated with 10 or 50 mg·kg−1 nCUR 6 h prior to STZ challenge had up to 37% reduction in the glucose levels, while plain CUR (50 mg·kg−1) results in 12% reduction. This treatment with nCUR was accompanied by decreased islet or beta cell death, as shown by TUNEL assay and H&E staining. Both CUR and nCUR significantly decreased levels of inflammatory cytokines in pancreatic tissue homogenates that correlated well with minimal histiocytic infiltration. Pre‐treatment with nCUR, but not CUR, decreased 8‐oxo‐2′‐deoxyguanosine, a sensitive biomarker of ROS‐induced DNA damage, in pancreas. In normal rodents, daily dosing for 28 days, with nCUR (25‐100 mg·kg−1) did not cause any deleterious health issues by the carrier.Conclusions and ImplicationsTogether, these data indicate a potentially translatable dose of nCUR that is safe and efficacious in improving beta cell function, which could prevent T1DM.
Extracellular vesicles from bone marrow–derived mesenchymal stem cells protect against murine hepatic ischemia/reperfusion injury
Haga, Hiroaki , Borrelli, David A., Matsuda, Akiko , Parasramka, Mansi, Shukla, Neha , Lee, David D. , Yan, Irene K. , Patel, Tushar , Lee, David D

Liver Transplantation | April 13, 2017 | Volume: 23 | Issue: 6 | Pages: 791-803

10.1002/lt.24770 | PMID 28407355 Get It

Hepatic ischemia/reperfusion injury (IRI) and associated inflammation contributes to liver dysfunction and complications after liver surgery and transplantation. Mesenchymal stem cells (MSCs) have been reported to reduce hepatic IRI because of their reparative immunomodulatory effects in injured tissues. Recent studies have highlighted beneficial effects of extracellular vesicles from mesenchymal stem cells (MSC‐EV) on tissue injury. The effects of systemically administered mouse bone marrow–derived MSC‐EV were evaluated in an experimental murine model of hepatic IRI induced by cross‐clamping the hepatic artery and portal vein for 90 minutes followed by reperfusion for periods of up to 6 hours. Compared with controls, intravenous administration of MSC‐EV 30 minutes prior to IRI dramatically reduced the extent of tissue necrosis, decreased caspase 3–positive and apoptotic cells, and reduced serum aminotransferase levels. MSC‐EV increased hepatic messenger RNA (mRNA) expression of NACHT, LRR, and PYD domains‐containing protein 12, and the chemokine (C‐X‐C motif) ligand 1, and reduced mRNA expression of several inflammatory cytokines such as interleukin 6 during IRI. MSC‐EV increased cell viability and suppressed both oxidative injury and nuclear factor kappa B activity in murine hepatocytes in vitro. In conclusion, the administration of extracellular vesicles derived from bone marrow–derived MSCs may ameliorate hepatic IRI by reducing hepatic injury through modulation of the inflammatory response.Liver Transplantation 23 791–803 2017 AASLD.
Thomas E. Starzl, M.D., Ph.D. (1926–2017)
Rakela, Jorge , Fung, John J.

Hepatology | April 13, 2017 | Volume: 66 | Issue: 1 | Pages: 306-308

10.1002/hep.29214 | PMID 28407325 Get It

A cardiovascular prescreening protocol for unmonitored in‐office laryngology procedures
Madden, Lyndsay L. , Ward, Anne , Young, VyVy N. , Smith, Libby J. , Bryson, Paul C. , Clary, Matthew S. , Weissbrod, Phillip A., Bock, Jonathan M. , Blumin, Joel H. , Rosen, Clark A. , Weissbrod, Philip A. , Ward, John , Lott, David G. , Weissbrod, Phil, Clary, Matthew S , Weissbrod, Philip A

The Laryngoscope | April 13, 2017 | Volume: 127 | Issue: 8 | Pages: 1845-1849

10.1002/lary.26481 | PMID 28407258 Get It

ObjectivesCurrently, there are no cardiovascular (CV) preprocedure screening parameters for patients undergoing in‐office laryngeal procedures (IOLP). Studies have shown significant changes in CV measures for IOLP. The aim was to develop and evaluate a pre‐IOLP CV screening protocol.MethodsReview of IOLP literature and consultation with an anesthesiologist and cardiologist led to the development of CV parameters and questions related to four metabolic equivalents (METS) of work as a patient‐screening tool before IOLP. A separate cohort was screened with only a modified CV protocol. All patients were screened for heart rate (HR) and blood pressure (BP) elevation prior to the procedure. Need for further CV evaluation was characterized as systolic blood pressure BP >160, diastolic BP >100, and/or HR >110 beats/minute. Patients whose BP/HR exceeded these values were referred to their primary care physician (PCP) before re‐screening. If parameters were exceeded again at the second screen, then the procedure was done under monitored anesthesia care.ResultsThe first study phase included 56 patients. The fail rate was 40% largely related to four METS of work. The second study phase included 440 patients. The screen fail rate was 15 patients of 572 (2.6%). Of these, 12 patients of 132 (9.1%) failed the initial screen and were sent to their PCP for further evaluation, and five of 440 (1.4%) patients failed on the day of the procedure. Overall, five of 440 (1.5%) patients would qualify to have their site of service changed for their laryngology procedure from an unmonitored to a monitored setting due to the prescreening criteria.ConclusionFew patients needed further workup based upon the in‐office CV parameters set in this study. Patients with CV risk factors were identified by the screening protocol. Having established hemodynamic parameters in place may improve the safety of IOLP with a very low physician burden.Level of Evidence2b Laryngoscope, 127:1845–1849, 2017